Who We Are

In 1982 a significant acquisition in the United Kingdom added to Genzyme’s product line and manufacturing facilities. Koch Light Laboratories, a maker of industrial fine chemicals and reagents in Haverhill, Suffolk, became Genzyme Fine Chemicals. Four years later when its focus shifted to pharmaceuticals, it was renamed Genzyme Pharmaceuticals.

In 1994 Genzyme acquired Sygena AG, a Swiss facility focused on the production of high quality chemical intermediates and active pharmaceutical ingredients. The acquisition of the Sygena facility brought with it extensive peptide and amino acid derivative manufacturing capacity and capability while adding strength to an existing lipid development and manufacturing business.

Having undertaken numerous facility-wide upgrades and significant expansion over the past eight years, our Swiss facility has become the cornerstone of production and R&D for the Pharmaceuticals Division. In 1999, to better reflect our unified vision and the seamless working relationship between our Swiss operations and our corporate offices in the United States, Sygena officially changed its name to Genzyme Pharmaceuticals. This facility located in Liestal, 15 km from Basel , holds a current GMP certificate and has been inspected by the Swiss Regulatory Agency, the US FDA, numerous customers and Genzyme Corporate Quality Compliance. To date these inspections have resulted in no reported critical observations.

Our Swiss scientists have state-of-the-art systems and equipment and extensive experience with a broad array of reaction types. In addition to manufacturing production-scale quantities of a variety of active pharmaceutical ingredients and critical excipients, Genzyme Pharmaceuticals is working closely with some of the worlds leading drug companies to develop and supply the next generation of pharmaceuticals and drug delivery technologies to help satisfy unmet medical needs worldwide.

Terms and Conditions of Use | Privacy Policy | © 2002-2008 Genzyme Corporation. All rights reserved.